


Elpis Biopharma signs MoU with NCCS to conduct translational cell therapy research in Singapore

28 July 2025 | News

Accelerating the delivery of potential groundbreaking new cancer therapies to patients in Singapore



US-based startup Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumours, has announced the signing of a Memorandum of Understanding (MoU) with the National Cancer Centre Singapore (NCCS).

The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.

As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC 002 and EPC-003, with the goal of expanding their translational relevance across multiple tumour types.

Plans are also underway for Elpis to establish a laboratory space at NCCS and co share its equipment to enable more integrated and efficient collaboration. NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.